The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene ...

On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” ...

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

Amid a rebound in SPAC activity, the prolific “crossover” investor is aiming for its third blank-check merger since 2022 ...

Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...

In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...

The “Great Healthcare Plan” is vague, but would send money directly to ACA enrollees and entrench the pricing deals the ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

Startups raised $14.2 billion last year, the highest funding total since 2022. Health AI companies collected 54% of total ...

More than 3,000 prescriptions were written for Novo’s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached ...

Amid patent expirations, litigation and tariff costs, J&J says it expects more growth ahead, fueled in part by its blood ...